Drugs / CIS43LS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04329104 | Feb 2021 → Jan 2022 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIS43LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04329104 ↗ |
| Known as | VRC-MALMAB0100-00-AB | “VRC-MALMAB0100-00-AB (CIS43LS), a human monoclonal antibody, against naturally occurring Plasmodium falciparum (Pf) infection.” NCT04329104 ↗ |
| Modality | Monoclonal antibody | “CIS43LS is a monoclonal antibody” PMID 36317783 ↗ Oct 2022 |
| Route | Intravenous | “Administered via one-time intravenous infusion” NCT04329104 ↗ |